News

The ACAAI's new yardstick for pediatric asthma provides guidance on stepping-up asthma treatments to gain and maintain symptom control.

The statistical algorithm incorporates data including age, depression severity, neuroticism, and cognitive control to decide which patients with depression are most likely to benefit from the antidepressant sertraline.

New findings suggest that a specific hemoglobin production protein could be a target for therapy in sickle cell disease or beta-thalassemia.

The FDA has granted a breakthrough therapy for atezolizumab Tin combination with bevacizumab for the treatment of advanced or metastatic hepatocellular carcinoma.

Perhaps surprisingly, patients admitted during periods of higher occupancy had 15% lower odds of contracting Clostridium difficile infection.

Researchers have identified a unique mutation in a deceased transthyretin (TTR) amyloidosis patient, which sheds light on the disease and may help identify new targets for treatment.

Researchers found that tobacco users, regardless of what product-type they used, underestimated the risks nicotine exposure posed to children and the high rates of multiple tobacco use.

The first meta-analysis of AMD clinical meta-analyses shows many have methodological limitations—more so those sponsored by industry than those sponsored by governments.

The FDA has granted an orphan drug designation to Asceneuron SA for ASN120290, for the treatment of progressive supranuclear palsy.

A phase 3 trial evaluating the use of oral ganaxolone in children and young adults with CDKL5 Deficiency Disorder has been initiated.

Among men who have sex with men, the increased odds of a new HIV infection per HIV-positive partner was reduced by 91% for each partner with whom condoms were always used.

In a new study, Australian researchers present findings on how a simple blood test may reveal which cases of head and neck cancers will spread to other organs.

SYMTUZA has been approved by the FDA based on the data of a pair of 48-week pivotal phase 3 trials which showed the non-inferiority safety and efficacy of the drug versus a controlled regimen.

The paradigm of obesity is complex and requires a multi-disciplinary approach, but it is one of the most gratifying experiences for both the physicians and patient when they see the results of weight loss.

Results showed that participants with doctor-diagnosed asthma had a 38% increased risk of developing AF compared to those without asthma.

A probiotic hygiene system resulted in a greater reduction of healthcare-associated infections and surface bacteria than chlorine-based cleansers, including a 66.6% reduction of C. difficile.

Certain lots of the therapy, distributed under the Actavis label in the US, have been detected to have trace amounts of probably human carcinogen NDMA.

The FDA and EMA’s Committee for Orphan Medical Products granted an orphan drug designation to INZ-701 for the treatment of ENPP1 deficiency.

The double-blind, placebo-controlled, parallel-group study that aims to observe linaclotide 290 mcg in 600 adult patients with IBS-C in the US.

Researchers at Baylor College of Medicine find that mutations in the gene TRAF7 are associated with a multisystem disorder presented by 7 patients.

Pivotal clinical trial, CONNECT-FX, commences to evaluate CBD gel as a treatment for fragile X syndrome.

An examination of trials supporting the 46 therapies approved via the Breakthrough Therapy designation has shown that fewer data supports their approval than what may be believed.

The antiviral treatment for patients at high risk of complications from influenza met the primary objective of efficacy measured by time to improvement of symptoms compared to placebo.

Researchers compared the cost-effectiveness of vancomycin, fidaxomicin, and bezlotoxumab with vancomycin as treatments for treating the first recurrence of Clostridium difficile infection.

Emixustat has been shown in previous preclinical analysis to slow the visual cycle and inhibit the activity of RPE65 and associated loss of photoreceptors associated with RPE dysfunction.

Positive data for the add-on therapy for patients with type 2 diabetes and chronic kidney disease will be presented at an upcoming medical meeting.

Study performed by researchers at Juntendo University reveals molecular mechanisms that trigger CALR-mutant myeloproliferative neoplasms (MPNs).

More treatments are needed for ALS, beyond the available riluzole and edaravone.